A Yale Cancer Center clinical trial combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer disclosed a 71% pathologic complete response to the combination treatment in the initial phase I trial.
More...